Neuromuscular junction disorders beyond myasthenia gravis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Autoimmune neuromuscular junction disorders present complex diagnostic and therapeutic challenges.
• Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder affecting neuromuscular transmission.
• Myasthenia gravis and Isaacs syndrome are other significant autoimmune neuromuscular junction disorders.

Purpose of the Study:

• To provide an overview of recent data on three autoimmune neuromuscular junction disorders.
• To highlight the FDA approval of amifampridine for Lambert-Eaton myasthenic syndrome (LEMS).
• To discuss updates in diagnostic criteria and antibody testing for these conditions.

Main Methods:

• Review of recent clinical studies and FDA approvals.
• Analysis of diagnostic advancements in electrophysiology.
• Evaluation of updated antibody testing recommendations.

Main Results:

• Amifampridine (3,4-Diaminopyridine) is FDA-approved for symptomatic LEMS treatment, showing significant efficacy with minimal side effects.
• Updated electrodiagnostic criteria for LEMS include 10-second exercise and incremental response thresholds.
• Myasthenia-gravis Lambert-Eaton overlap syndrome (MLOS) has been identified as a distinct entity.
• Leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated like-2 (CASPR2) autoantibody tests are now recommended for Isaacs syndrome, replacing voltage-gated calcium channel antibodies.

Conclusions:

• Amifampridine represents a significant therapeutic advance for LEMS.
• Refined diagnostic approaches improve the identification of LEMS and related disorders.
• Updated antibody testing strategies enhance diagnostic accuracy for Isaacs syndrome.